Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor
- 1Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803 USA
Abstract
Introduction: The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathways mediate signaling by multiple cytokines and growth factors critical for inflammation and immune regulation. Povorcitinib (INCB054707) is an oral JAK1 inhibitor designed to achieve high selectivity over JAK2 and minimize off-target hematologic effects. This study comprehensively assessed the in vitro selectivity and potency of povorcitinib relative to the JAK inhibitors upadacitinib, abrocitinib, baricitinib, and tofacitinib.
Methods: Povorcitinib and comparator compounds were characterized using enzymatic assays, full kinome profiling across 370 kinases, cytokine reporter assays, human whole-blood STAT phosphorylation assays, and cell viability studies.
Results: Povorcitinib demonstrated potent, selective JAK1 inhibition with minimal activity against JAK2, JAK3, and TYK2, showing ≥ 50-fold selectivity over JAK2 in most assays, exceeding that of other JAK inhibitors. Kinome screening confirmed minimal off-target activity. In cell-based assays, povorcitinib selectively inhibited interleukin (IL)-6– and IL-2–mediated JAK1 signaling with minimal inhibition of thrombopoietin (TPO)-mediated JAK2 signaling, achieving up to 52-fold functional JAK1 selectivity in cytokine reporter assays and greater than tenfold selectivity in human whole blood. In contrast, other selective JAK1 inhibitors, such as upadacitinib, displayed near-equipotent JAK1/JAK2 inhibition in whole-blood assays. Povorcitinib displayed no cytotoxicity at concentrations > 5000 nM in HEK293, HEPG2, HUVEC, and HLF cells, which are JAK-independent. Across orthogonal assays, povorcitinib consistently exhibited the highest JAK1 selectivity among the JAK inhibitors evaluated.
Conclusions: These data, together with its favorable pharmacokinetic and emerging clinical safety profile, highlight the potential for povorcitinib as a highly selective, next-generation JAK1 inhibitor.
Related
- Comparative and Histology-Aware Bioinformatic Characterization of FAM171A1 and FAM171A2 in Sarcoma: Expression, Prognostic, and Immune Associations
- Comparative Metabolomic Profiling of Amino Acids in Dried Blood Spots from Dichorionic and Monochorionic Twins Complicated by Selective Fetal Growth Restriction and Twin-to-Twin Transfusion Syndrome
- Advances in pharmacologic management of obesity: oral semaglutide for weight management
- Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence
- Optimisation and mechanistic characterization of a selective benzoxazine-based MAP4K4 inhibitor in pancreatic cancer cells.
BibTeX
@article{wass2026comparative,
title = {{Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor}},
author = {Brittney Wass and Aidan M. Fenix and Nina Zolotarjova and Alex Margulis and Guofeng Zhang and Dominic Sales and Maryanne Covington and Leandro L. Santos and Chryssa Kanellopoulou and Ricardo Macarrón},
journal = {Dermatology and Therapy},
year = {2026},
month = oct,
doi = {10.1007/s13555-026-01910-y},
url = {https://doi.org/10.1007/s13555-026-01910-y},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor
AU - Brittney Wass
AU - Aidan M. Fenix
AU - Nina Zolotarjova
AU - Alex Margulis
AU - Guofeng Zhang
AU - Dominic Sales
AU - Maryanne Covington
AU - Leandro L. Santos
AU - Chryssa Kanellopoulou
AU - Ricardo Macarrón
PY - 2026
DA - 2026/10/02
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01910-y
UR - https://doi.org/10.1007/s13555-026-01910-y
AB - Introduction: The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathways mediate signaling by multiple cytokines and growth factors critical for inflammation and immune regulation. Povorcitinib (INCB054707) is an oral JAK1 inhibitor designed to achieve high selectivity over JAK2 and minimize off-target hematologic effects. This study comprehensively assessed the in vitro selectivity and potency of povorcitinib relative to the JAK inhibitors upadacitinib, abrocitinib, baricitinib, and tofacitinib. Methods: Povorcitinib and comparator compounds were characterized using enzymatic assays, full kinome profiling across 370 kinases, cytokine reporter assays, human whole-blood STAT phosphorylation assays, and cell viability studies. Results: Povorcitinib demonstrated potent, selective JAK1 inhibition with minimal activity against JAK2, JAK3, and TYK2, showing ≥ 50-fold selectivity over JAK2 in most assays, exceeding that of other JAK inhibitors. Kinome screening confirmed minimal off-target activity. In cell-based assays, povorcitinib selectively inhibited interleukin (IL)-6– and IL-2–mediated JAK1 signaling with minimal inhibition of thrombopoietin (TPO)-mediated JAK2 signaling, achieving up to 52-fold functional JAK1 selectivity in cytokine reporter assays and greater than tenfold selectivity in human whole blood. In contrast, other selective JAK1 inhibitors, such as upadacitinib, displayed near-equipotent JAK1/JAK2 inhibition in whole-blood assays. Povorcitinib displayed no cytotoxicity at concentrations > 5000 nM in HEK293, HEPG2, HUVEC, and HLF cells, which are JAK-independent. Across orthogonal assays, povorcitinib consistently exhibited the highest JAK1 selectivity among the JAK inhibitors evaluated. Conclusions: These data, together with its favorable pharmacokinetic and emerging clinical safety profile, highlight the potential for povorcitinib as a highly selective, next-generation JAK1 inhibitor.
SN - 2193-8210
SN - 2190-9172
ER -